Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1451-1459

  Gu, Shaohua ^a   Wu, Qihan ^b   Zhao, Xueying ^a   Wu, Wenting ^a   Gao, Zhiqiang ^c   Tan, Xiaoming ^d   Qian, Ji ^a   Chen, Hongyan ^a   Xie, Yi ^a   Jin, Li ^a   Han, Baohui ^c   Lu, Daru ^a  

^a FUDAN UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; MACROPHAGE MIGRATION INHIBITION FACTOR; PLATINUM; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANEMIA; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; FEMALE; GASTROINTESTINAL DISEASES; GENOTYPING TECHNIQUES; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84864303823     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02323.x     Document Type: Article

References (42)

1. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-8.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
3. Rabik C, Dolan M. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
4. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771-5.
5. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997; 349: 849.
6. Nicholson D, Thornberry N. Caspases: killer proteases. Trends Biochem Sci 1997; 22: 299-306.
7. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15: 269-90.
8. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22: 8543-67.
9. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-60.
10. Bodmer JL, Holler N, Reynard S et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-3.
11. Hajra K, Liu J. Apoptosome dysfunction in human cancer. Apoptosis 2004; 9: 691-704.
12. Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89.
13. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998; 1: 949-57.
14. Adrain C, Martin SJ. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci 2001; 26: 390-7.
15. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-56.
16. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
17. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
18. Bach J, Rinn B, Meyer B, Dodel R, Bacher M. Role of MIF in inflammation and tumorigenesis. Oncology 2008; 75: 127-33.
19. Mitchell R. Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 2004; 16: 13-9.
20. Bucala R, Donnelly S. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 2007; 26: 281-5.
21. Jung H, Seong H, Ha H. Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem 2008; 283: 20383.
22. Mitchell R, Liao H, Chesney J et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002; 99: 345.
23. Liu L, Chen J, Ji C et al. Macrophage Migration Inhibitory Factor (MIF) interacts with bim and inhibits bim-mediated apoptosis. Mol Cells 2008; 26: 193.
24. Liu L, Ji C, Chen J et al. A global genomic view of MIF knockdown-mediated cell cycle arrest. Cell Cycle 2008; 7: 1678-92.
25. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092-100.
26. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-65.
27. Rajaraman P, Wang SS, Rothman N et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 2007; 16: 1655-61.
28. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
29. Wu W, Zhang W, Qiao R et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res 2009; 15: 3889-95.
30. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-9.
31. Hosgood H III, Baris D, Zhang Y et al. Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 2008; 26: 148-51.
32. Lan Q, Zheng T, Chanock S et al. Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 2007; 28: 823.
33. Conne B, Stutz A, Vassalli J. The 3' untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 2000; 6: 637-42.
34. Kuersten S, Goodwin E. The power of the 3' UTR: translational control and development. Nat Rev Genet 2003; 4: 626-37.
35. Carthew R, Sontheimer E. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
36. Allan S, Smyth J. Small intestinal mucosal toxicity of cis-platinum-comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 1986; 53: 355.
37. Wilson A, Symons J, McDowell T, McDevitt H, Duff G. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195.
38. Laws S, Perneczky R, Wagenpfeil S et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat 2005; 26: 29-35.
39. Saiki M, Baker A, Williams-Gray C et al. Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 890.
40. Wang S, Cozen W, Cerhan J et al. Immune Mechanisms in Non-Hodgkin Lymphoma: joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non-Hodgkin Lymphoma Risk Factors. Cancer Res 2007; 67: 5042.
41. Gaudet M, Egan K, Lissowska J et al. Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet 2007; 121: 483-90.
42. Bouhaha R, Baroudi T, Ennafaa H et al. Study of TNF [alpha]-308G/A and IL6-174G/C polymorphisms in type 2 diabetes and obesity risk in the Tunisian population. Clin Biochem 2010; 43: 549-52.